Arvinas and Pfizer Reveal Early Phase 1b Outcomes from TACTIVE-U Vepdegestrant-Abemaciclib Study at 2024 SABC Symposium
Arvinas, Inc., a biotechnology company in clinical development phases, together with Pfizer Inc., disclosed initial findings from the phase 1b segment of the TACTIVE-U study. This study explores the efficacy of the vepdegestrant and abemaciclib combination in patients with locally […]